Skip to main content
. 2021 May 7;12:680068. doi: 10.3389/fimmu.2021.680068

Figure 9.

Figure 9

PKM2 is over-expressed in SLE patients and correlated with activation of monocytes, DCs and B cells. (A, B) MDMs, derived from PBMCs from healthy donors, were pretreated with PKM2-IN (5 μM) for 2 hours followed by stimulations of LPS (100 ng/mL), R848 (1 μg/mL) and CpG-2006S (1 μM). FACS analysis of CD86 and CD40 expressions on MDMs at 24 hours. (C, D) CD19+ B cells, isolated from PBMCs from healthy donors, were pretreated with PKM2-IN (5 μM) for 2 hours followed by stimulations of R848 (1 μg/mL) and CpG-2006S (1 μM). FACS analysis of CD86 and CD40 expressions on CD19+ B cells at 24 hours. Data are representative from one out of four biological replicates, each with three technical replicates. Error bars represent S.E.M. (E) FACS analysis of PKM2 protein expression on CD14+ monocytes in PBMCs from SLE patients (n=48) and healthy donors (n=50). (F) Positive correlation between PKM2 and CD86 in CD14+ monocytes from PBMCs of SLE patients (n=48). (G) Positive correlation between PKM2 and CD40 in CD14+ monocytes from PBMCs of SLE patients (n=48). (H) FACS analysis of PKM2 protein expression on CD11c+ dendritic cells in PBMCs from SLE patients (n=48) and healthy donors (n=50). (I) Positive correlation between PKM2 and CD86 in CD11c+ dendritic cells from PBMCs of SLE patients (n=48). (J) Positive correlation between PKM2 and CD40 in CD11c+ dendritic cells from PBMCs of SLE patients (n=48). (K) FACS analysis of PKM2 protein expression on CD19+ B cells in PBMCs from SLE patients (n=48) and healthy donors (n=50). (L) Positive correlation between PKM2 and CD86 in CD19+ B cells from PBMCs of SLE patients (n=48). (M) Positive correlation between PKM2 and CD40 in CD19+ B cells from PBMCs of SLE patients (n=48). Error bars represent S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by ANOVA tests or t-tests. Correlation coefficients were calculated using linear regression analysis.